Canadian urology research gains momentum
2013 CUA Astellas grant recipients announced
MARKHAM, ON, Aug. 29, 2013 /CNW/ - The Canadian Urological Association (CUA) and Astellas Pharma Canada, Inc. are proud to partner for a second year in support of the CUA Astellas Research Grant Program.
Last year, Astellas pledged $750,000 over a period of five years to support Canadian peer-reviewed urology research and promote excellence in urological research. The ultimate goal of the grant program is to improve patient care.
With a detailed application review process based on a defined set of criteria, this year Dr. Rendon invited Dr. Alan So, a prominent CUA member from Vancouver, to co-chair the Scientific Council. Together, they shared the duties of the review process and oversaw the review committee.
The CUA Astellas Research Grant is beginning to gain both prominence and momentum within the urology research community, resulting in 19 applications for the 2013 competition. We are pleased to announce the 2013 recipients, who include:
Dr. Kourosh Afshar University of British Columbia, Vancouver, BC Project Title: Voiding disorders and autonomic NS activity in children
Dr. Sumit Dave University of Western Ontario, London, ON Project Title: A clinical trial to determine the extent to which probiotic therapy reduces side effects of antibiotic prophylaxis in pediatric neurogenic bladder patients with a history of recurrent urinary tract infections
Dr. Alp Sener University of Western Ontario, London, ON Project title: Novel delivery method of supplemental hydrogen sulphide and caspace-3 siRNA during mechanical perfusion are protective in a donation after cardiac death model of porcine renal transplantation
"This innovative research can lead to important discoveries that may ultimately change the treatment landscape for patients with urological conditions," says Michael Tremblay, President, Astellas Pharma Canada, Inc. "It is tremendously exciting for us to support the work of these doctors because their research has the potential to improve quality of life for Canadian patients."
About the Canadian Urological Association (CUA) The CUA Mission is to represent and provide a voice for all Canadian urologists and to foster dedication of all members of the profession toward ensuring the highest possible standard of urologic care for Canadians.
The goals of the CUA are to:
-- To foster and promote excellence in urologic practice through education and research. -- To provide leadership in promoting evidence based clinical practice through the development of practice guidelines. -- To foster and promote life-long learning by Canadian urologists through continuous professional development. -- To provide leadership in public education for urologic diseases. -- To represent Canadian urology in developing and fostering partnerships while maintaining the highest educational and ethical standards. -- To represent the Canadian urologic community in relationships with national and international medical societies. More information about CUA can be found at www.cua.org About Astellas Pharma Canada, Inc. Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a Canadian affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. In Canada, Astellas has an intense commercial focus on five therapeutic areas - Urology, Immunology, Infectious Disease, Dermatology and Oncology. For more information about Astellas Pharma Canada, Inc., please visit the corporate website: www.astellas.ca
SOURCE Astellas Pharma Canada, Inc.
Tiffany Pizioli Executive Director, CUA Office of Education Canadian Urological Association (514) 395-0376 ext. 44 email@example.com
Naomi Côté Corporate Communications Astellas Pharma Canada, Inc. (905) 946-5648 firstname.lastname@example.org
To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/August2013/29/c8328.html
CO: Astellas Pharma Canada, Inc. ST: Ontario NI: MTC
-0- Aug/29/2013 12:30 GMT